What happened with IRTC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
iRhythm Holdings, Inc. helps physicians diagnose irregular heart rhythms while patients go about their daily lives. Its Zio monitor and Zio AT patches record electrical signals from the heart. The company analyzes those recordings with its cloud-based ZEUS software and FDA-cleared algorithms, has qualified technicians check the findings, and sends reports to the ordering physician. Its mobile cardiac telemetry service also transmits data and provides technician notifications during monitoring when specified clinical criteria are met.
Almost all revenue comes from the United States. Contracted insurers supply most revenue, and Medicare, administered by CMS, is another major payer; hospitals and physician practices also buy services directly. Revenue depends on physicians ordering tests, payers covering them and the reimbursement rates they set. For long-term monitoring, patients must return the patch so iRhythm can process the stored data and issue the report needed to support a payment claim.
As a Medicare-enrolled diagnostic testing provider, iRhythm can provide services only with a valid order from a licensed healthcare provider and cannot directly solicit patients for diagnostic procedures. Many commercial insurers also require it to maintain Medicare enrollment and accreditation. Its systems are not intended for emergencies or patients who need inpatient monitoring for suspected life-threatening arrhythmias.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
iRhythm’s results hinge on monitoring volumes and payor reimbursement; Royal Philips’ BioTelemetry is an important direct competitor to watch that is missing from this list.
Boston Scientific’s Preventice Solutions competes for physician-ordered remote heart-monitoring business with iRhythm, which earns revenue from wearable patches and analysis services. Watch Preventice’s acceptance among doctors and institutions, since both compete on ease of use, price and reimbursement.
Baxter International’s BardyDx and Welch Allyn businesses challenge iRhythm both commercially and in court: they compete in heart monitoring while patients go about daily life and have brought patent litigation against it.
GE HealthCare competes with iRhythm’s patch-based monitoring by selling traditional portable ECG recorders, called Holter monitors, for diagnosing irregular heart rhythms. GE HealthCare sells medical equipment to hospitals and health systems; its Holter offering, rather than its broader equipment sales, is the relevant competition to watch.
Boston Scientific Corp. earningsBSX
Boston Scientific's report can show whether doctors and institutions are taking up its Preventice remote heart-monitoring services, a signal of the competition iRhythm faces.
If Boston Scientific reports Preventice uptake, compare it with changes in iRhythm's Zio service volume, and note any discussion of price or reimbursement. Stronger uptake among doctors and institutions would mean more competition for the same remote-monitoring demand, potentially making it harder for iRhythm to win accounts or maintain pricing. Weaker uptake would point to less pressure from this rival.
iRhythm Holdings, Inc. earningsThis company
iRhythm's report will show whether growth in Zio monitoring services is turning into revenue, or whether claim denials are eating into that gain.
Read changes in Zio service volume and net revenue alongside gross margin and any rise in contractual allowance reserves tied to claim denials. If volume lifts revenue, gross margin holds, and denial-related reserves stay contained, more services are becoming collectible revenue without costs consuming much of the gain. If volume rises but revenue or margin lags while those reserves grow, payment problems are eroding the return from added services.
